Victory Capital Management Inc. Has $19.07 Million Stock Position in STERIS plc $STE

Victory Capital Management Inc. lessened its position in shares of STERIS plc (NYSE:STE) by 4.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 77,084 shares of the medical equipment provider’s stock after selling 3,565 shares during the quarter. Victory Capital Management Inc. owned about 0.08% of STERIS worth $19,074,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Steigerwald Gordon & Koch Inc. bought a new position in STERIS during the third quarter worth about $25,000. Cloud Capital Management LLC bought a new position in shares of STERIS during the 3rd quarter valued at about $29,000. Geneos Wealth Management Inc. grew its position in shares of STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 104 shares during the period. TruNorth Capital Management LLC bought a new stake in STERIS during the 3rd quarter worth approximately $37,000. Finally, Root Financial Partners LLC acquired a new stake in STERIS during the 3rd quarter worth approximately $39,000. 94.69% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, STERIS presently has an average rating of “Moderate Buy” and a consensus target price of $275.20.

Insider Buying and Selling at STERIS

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the sale, the director owned 705 shares in the company, valued at $167,233.05. This represents a 81.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 1.07% of the stock is owned by company insiders.

STERIS Stock Down 2.5%

Shares of STE stock opened at $221.99 on Wednesday. The firm’s fifty day moving average price is $253.13 and its two-hundred day moving average price is $251.21. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. STERIS plc has a 1 year low of $204.90 and a 1 year high of $269.44. The firm has a market capitalization of $21.77 billion, a P/E ratio of 30.96 and a beta of 1.05.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, meeting the consensus estimate of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.STERIS’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same period in the previous year, the business posted $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, equities analysts predict that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Tuesday, February 17th. This represents a $2.52 annualized dividend and a dividend yield of 1.1%. STERIS’s payout ratio is 35.15%.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.